Yusuke Matsuura

Prof. Dr. Yusuke Matsuura

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Gynecologic Oncology
Verified
Journal Article
Closed access
YMYusuke Matsuura
Yusuke Matsuura
GRGreg Robertson
Greg Robertson
DMDonald E. Marsden
Donald E. Marsden
SKSoo-Nyung Kim
Soo-Nyung Kim
VGVal Gebski
Val Gebski
NHNeville F. Hacker
Neville F. Hacker

24 January 2006 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
YMYusuke Matsuura
Yusuke Matsuura
TKT. Kawagoe
T. Kawagoe
NTN. Toki
N. Toki
MTM. Tanaka
M. Tanaka
MKM. Kashimura
M. Kashimura

1 March 2004 in Gynecologic Oncology
Verified
Journal Article
Closed access
YMYusuke Matsuura
Yusuke Matsuura
KYKosuke Yasunaga
Kosuke Yasunaga
HKHiroko Kuroki
Hiroko Kuroki
HIHirohide Inagaki
Hirohide Inagaki
MKMasamichi Kashimura
Masamichi Kashimura

21 July 2010 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
YMYusuke Matsuura
Yusuke Matsuura
MKMitsuyasu Kitajima
Mitsuyasu Kitajima
THToru Hachisuga
Toru Hachisuga
ATAkihide Tanimoto
Akihide Tanimoto
NONaohumi Okura
Naohumi Okura
IKIkuo Kihara
Ikuo Kihara

19 April 2022 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YKYasuyuki Kinjo
Yasuyuki Kinjo
YMYusuke Matsuura
Yusuke Matsuura
TOTakayuki Ohguri
Takayuki Ohguri
YAYoko Aoyama
Yoko Aoyama
MMMidori Murakami
Midori Murakami
KYKiyoshi Yoshino
Kiyoshi Yoshino
There is currently controversy regarding the criteria for low and intermediate risk of cervical cancer (CC) after surgery. In the present study, the Gynecology Oncology Group (GOG) score was used to detect intermediate risk. Adjuvant radiotherapy was applied in the case of a GOG score >120. The present study aimed to evaluate the validity of the recurrence risk classification using the GOG score for stage IB‑IIA node‑negative CC. All cases of stage IB‑IIA node‑negative CC who underwent radical surgery between February 2007 and December 2015 were retrospectively reviewed. The GOG scores were determined from clinical and pathological findings and accordingly, subjects were divided into 4 groups: A, ≤40; B, >40 and ≤70; C, >70 and ≤120; and D, >120. Overall survival (OS) and recurrence‑free survival (RFS) curves were generated using the Kaplan‑Meier method. The log‑rank test produced an estimated P‑value by comparing the OS and RFS of group A (low‑score group) with those of others. The present study included 61 patients (mean age, 47.82 years; age range, 22‑76 years) and the median follow‑up was 79 (39‑149) months. Of these, 60 patients were observed for at least 60 months. During the follow‑up period, the OS and RFS rates of group C were 94.7 and 84.2%, respectively, while those of group D were 100 and 91.7%, respectively; the OS and RFS of groups A and B were 100%. Log‑rank tests for all OS and RFS indicated no significant differences compared to group A. It was indicated that a GOG score ≤70 does not require adjuvant therapy; however, a GOG score >70 requires consideration of adjuvant therapy based on the risk factors which constitute the score.

10 February 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
HHHiroshi Harada
Hiroshi Harada
THToru Hachisuga
Toru Hachisuga
YHYoshikazu Harada
Yoshikazu Harada
MSMami Shibahara
Mami Shibahara
MMMidori Murakami
Midori Murakami
KYKiyoshi Yoshino
Kiyoshi Yoshino
Background: The immunoreactive (IR) subtype is one of the subtypes of high-grade serous ovarian carcinoma (HGSOC) with intra-tumoral lymphocytic infiltration. A positive prognostic correlation between IR subtype and R0 + optimal surgery has been reported. This study investigates the prognostic significance of tumor-infiltrating lymphocytes (TILs) in the suboptimal surgery group of HGSOCs. Methods: After reviewing 318 malignant ovarian tumors detected in our database between 2000 and 2017, 74 HGSOCs with supplemental p53 immunostaining were selected. Differences in progression-free survival (PFS) and overall survival (OS) between the two groups of the IR subtype and the other subtypes were investigated. Based on pathological findings, HGSOCs were divided into two groups: those with or without abundant TILs. Results: Abundant TILs were detected in 17 cases of HGSOC (22.9%). Clinicopathological characteristics including age, CA125, FIGO stage, and residual disease did not show significant differences between the two groups. Lymph node metastasis was more common in the IR subtype group (p = 0.04). In the suboptimal surgery group, the 5-year PFS and OS (Kaplan–Meier estimates) in cases with (n = 10) or without (n = 21) abundant TILs were 10% and 0% (p = 0.097) and 70% and 28.5% (p = 0.012), respectively. The median time (range) to OS in cases with or without abundant TILs were 58 (34–81) months and 39 (22–55) months, respectively. Multivariate analysis in OS showed significant differences in TILs. Conclusions: Abundant intra-tumoral lymphocytic infiltration is an independent and favorable prognostic indicator for the suboptimal surgery group in HGSOCs and is associated with treatment response via cancer immunity.